Mochi Health Compounded GLP-1vsEden Compounded GLP-1

You take a weekly subcutaneous injection of compounded semaglutide (a GLP-1 receptor agonist) or compounded tirzepatide (a dual GIP/GLP-1 agonist). These hormones slow how fast your stomach empties and signal fullness to the brain, so you eat less without feeling deprived. A Mochi clinician sets your starting dose and titrates it upward over weeks to balance results against side effects.

You self-administer a once-weekly subcutaneous injection of compounded semaglutide or tirzepatide. Semaglutide activates GLP-1 receptors; tirzepatide activates both GIP and GLP-1 receptors. The result is slower stomach emptying, increased fullness, and reduced appetite, which lowers calorie intake. An Eden provider sets and titrates the dose over time.

Mochi uses the same active molecules studied in landmark trials. In STEP 1, branded semaglutide 2.4 mg produced about 14.9% average body-weight loss over 68 weeks; in SURMOUNT-1, branded tirzepatide 15 mg produced about 20.9% over 72 weeks. Compounded formulations are not separately FDA-tested, so trial results for branded drugs are a reference point, not a guarantee. Individual results vary.

Eden's medications share active ingredients with branded drugs studied in major trials: STEP 1 showed branded semaglutide produced roughly 14.9% average weight loss over 68 weeks, and SURMOUNT-1 showed branded tirzepatide produced up to about 20.9% over 72 weeks. Compounded versions are not independently FDA-tested, so these figures are context, not a promise. Individual results vary.

Most side effects are gastrointestinal (nausea, diarrhea, constipation, vomiting) and tend to ease as your body adjusts and as the dose is titrated slowly. Rare but serious risks include pancreatitis and gallbladder disease. Because the product is compounded, dosing-error and quality risks exist; report unusual symptoms to your clinician promptly. This is educational information, not medical advice.

Gastrointestinal side effects (nausea, constipation, diarrhea) are the most common and usually improve with slow dose titration. Serious but uncommon risks include pancreatitis and gallbladder issues. Because the medication is compounded rather than FDA-approved, report any unexpected symptoms to your provider. This is educational, not medical advice.

As of September 2026, Mochi's membership is $39 for the first month and $79/month after that, and compounded semaglutide starts at $60/month on top of the membership — about $139/month combined at the lowest price point, before dose increases. Tirzepatide costs more. Insurance does not cover compounded medication. Check the current medication price for your dose at checkout.

Plan for $149 the first month and $229/month thereafter for semaglutide, or $249 then $329/month for tirzepatide, as of May 2026. Multi-month bundles cut the effective monthly rate. The price is all-in (visit, medication, free shipping) and is not covered by insurance because the product is compounded.

Generally for US adults seeking medical weight management who clear a clinician's telehealth evaluation. Not appropriate for people with a personal or family history of medullary thyroid carcinoma or MEN 2, and not for use during pregnancy. State availability varies.

For US adults seeking medical weight management who pass a telehealth clinical review. Not for people with a history of medullary thyroid carcinoma or MEN 2, and not for use in pregnancy. Availability and product options vary by state.